Parexel International, slashing jobs after a rough run, posted some modest revenue gains in its fiscal fourth quarter, and now the CRO is looking to build some momentum with a jump in new business.
Parexel is expanding its efforts in so-called model-based drug development, using data analytics to flesh out a drug's potential safety, efficacy and interactions before beginning a clinical trial.
CRO giant Parexel is planning to shed about 850 jobs over the next year in an effort to cut costs as it lowers its financial expectations for the quarter.
CRO giant Parexel has updated its technology for patient randomization and clinical supply management, touting the latest version as a valuable tool for speeding up the process of designing studies.
CRO giant Parexel posted flat revenue last quarter, paring back its full-year expectations in the face of currency headwinds and client delays.
CRO giant Parexel International has unveiled three new education programs in partnership with schools around the world, lending its expertise in hopes of training the next generation of clinical researchers.
CRO giant Parexel International is acquiring an Indian company devoted to pharmacovigilance, looking to expand its share of the global market for managing drug safety data.
CRO giant Parexel International has expanded its Rolodex of clinical trial sites to more than 180 around the world, a network the company says allows it to more quickly find patients for studies.
Despite posting an uptick in revenue last quarter, CRO giant Parexel International is slightly lowering its outlook for fiscal 2015, betting that its backlog of deals will eventually make up for some soft sales.
Parexel is leasing a North Carolina building from GlaxoSmithKline, part of a deal between the two in which the CRO will absorb some researchers on the way out as the drugmaker mounts a major restructuring.